Diplomat Pharmacy selected to Pfizer's limited distribution panel

FLINT, Mich. — Diplomat Pharmacy announced Wednesday that it has been selected to Pfizer's limited-distribution panel for Xalkori, Bosulif, Inlyta and Sutent.

 

The four limited distribution therapies have each received approval from the Food and Drug Administration for the treatment of specific cancers.

 

"We are proud to be selected to Pfizer's limited-distribution panel for these four important oncology treatments," said Gary Kadlec, president of Diplomat. "Diplomat's high-touch, patient-centric approach to care and expertise in dispensing limited-distribution drugs supports our commitment to the distribution of these therapies in accordance with our high standards of excellence."

 

Bosulif and Sutent were previously available through open distribution, with Diplomat also having access to Inlyta as a member of Pfizer's prior limited-distribution panel for the drug.

 

Diplomat has access to dispense Xalkori, Bosulif, Inlyta and Sutent immediately.